Similar articles for PMID: 17913723

Year	Number of Results
1999	1
2000	1
2001	2
2002	3
2003	1
2004	11
2005	7
2006	8
2007	5
2008	10
2009	10
2010	10
2011	9
2012	4
2013	3
2015	2
2019	2
2024	0

1

Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, González-Lahoz J, Soriano V. Poveda E, et al. J Antimicrob Chemother. 2007 Dec;60(6):1409-10. doi: 10.1093/jac/dkm372. Epub 2007 Oct 3. J Antimicrob Chemother. 2007. PMID: 17913723 No abstract available.

2

Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C. Lapadula G, et al. Antivir Ther. 2008;13(4):601-5. Antivir Ther. 2008. PMID: 18672539

3

[Etravirine: genetic barrier and resistance development].

Llibre JM, Santos JR, Clotet B. Llibre JM, et al. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:32-9. doi: 10.1016/S0213-005X(09)73217-3. Enferm Infecc Microbiol Clin. 2009. PMID: 20116626 Review. Spanish.

4

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.

Cotte L, Trabaud MA, Tardy JC, Brochier C, Gilibert RP, Miailhes P, Trépo C, André P. Cotte L, et al. J Med Virol. 2009 Apr;81(4):672-7. doi: 10.1002/jmv.21461. J Med Virol. 2009. PMID: 19235860

5

Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?

Scott C, Grover D, Nelson M. Scott C, et al. AIDS. 2008 May 11;22(8):989-90. doi: 10.1097/QAD.0b013e3282fa75df. AIDS. 2008. PMID: 18453859 Clinical Trial.

6

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.

Poveda E, de Mendoza C, Pattery T, González Mdel M, Villacian J, Soriano V. Poveda E, et al. AIDS. 2008 Nov 12;22(17):2395-8. doi: 10.1097/QAD.0b013e32831692fb. AIDS. 2008. PMID: 18981781

7

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group. Descamps D, et al. J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21. J Antimicrob Chemother. 2010. PMID: 20965891

8

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.

Neogi U, Shet A, Shamsundar R, Ekstrand ML. Neogi U, et al. AIDS. 2011 May 15;25(8):1123-6. doi: 10.1097/QAD.0b013e328346269f. AIDS. 2011. PMID: 21505320 Free PMC article.

9

HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.

Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, Sen L. Aulicino PC, et al. Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571. Antivir Ther. 2010. PMID: 20587857

10

HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

Ghosn J, Chaix ML, Delaugerre C. Ghosn J, et al. AIDS Rev. 2009 Jul-Sep;11(3):165-73. AIDS Rev. 2009. PMID: 19654858 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

86 results

Results by year